103
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Urinary Excretion of Liver-Type FABP as a New Clinical Marker for the Progression of Obstructive Nephropathy

, , , , &
Pages 543-556 | Published online: 06 May 2014

References

  • Smith JM , StableinDM , MunozRet al. Contributions of the transplant registry: the 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr. Transplant. 11 ( 4 ), 366 – 373 ( 2007 ).
  • Chevalier RL , ThornhillBA , ForbesMSet al. Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy. Pediatr. Nephrol. 25 ( 4 ), 687 – 697 ( 2010 ).
  • Dear JW , YuenPS. Setting the stage for acute-on-chronic kidney injury.Kidney Int.74 ( 1 ), 7 – 9 ( 2008 ).
  • Ferguson MA , VaidyaVS , WaikarSSet al. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 77 ( 8 ), 708 – 714 ( 2010 ).
  • Levey AS , CoreshJ , GreeneTet al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 53 ( 4 ), 766 – 772 ( 2007 ).
  • Mehta RL , KellumJA , ShahSVet al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11 ( 2 ), R 31 ( 2007 ).
  • Han WK , WagenerG , ZhuY , WangS , LeeHT. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery.Clin. J. Am. Soc. Nephrol.4 ( 5 ), 873 – 882 ( 2009 ).
  • Chevalier RL . Obstructive nephropathy: towards biomarker discovery and gene therapy.Nat. Clin. Pract. Nephrol.2 ( 3 ), 157 – 168 ( 2006 ).
  • Glatz JF , vander Vusse GJ. Cellular fatty acid-binding proteins: their function and physiological significance.Prog. Lipid Res.35 ( 3 ), 243 – 282 ( 1996 ).
  • Kamijo A , SugayaT , HikawaAet al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am. J. Pathol. 165 ( 4 ), 1243 – 1255 ( 2004 ).
  • Nakamura T , SugayaT , NodeKet al. Urinary excretion of liver-type fatty acid-binding protein in contrast mediun-induced nephropathy. Am. J. Kidney Dis. 47 ( 3 ), 439 – 444 ( 2006 ).
  • Portilla D , DentC , SugayaTet al. Live fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 73 ( 4 ), 465 – 472 ( 2008 ).
  • Kamijo A , SugayaT , HikawaAet al. Clinical evaluation of urinary excretion of liver-type fatty acid binding protein as a marker for monitoring chronic kidney disease: a multi-center trial. J. Lab. Clin. Med. 145 ( 3 ), 125 – 133 ( 2005 ).
  • Mou S , WangQ , NiZet al. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Clin. Chim. Acta 413 ( 1–2 ), 187 – 191 ( 2012 ).
  • Kamijo A , SugayaT , HikawaAet al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol. Cell Biochem. 284 ( 1–2 ), 175 – 182 ( 2006 ).
  • Haase M , BellomoR , DevarajanPet al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 54 ( 6 ), 1012 – 1024 ( 2009 ).
  • Kamijo A , SugayaT , KimuraK. Urinary fatty acid binding protein in renal disease.Clin. Chim. Acta374 ( 1–2 ), 1 – 7 ( 2006 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.